Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of rosuvastatin and furosemide in Chinese peritoneal dialysis patients
ChiCTR2600124934Phase 4Completed
- Sponsor
- Peking University Third Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rosuvastatin and furosemide in chronic kidney disease (CKD) and end-stage kidney disease (ESKD), sponsored by Peking University Third Hospital. Primary endpoints: Rosuvastatin plasma concentration and Furosemide plasma concentration. Started May 2026; status: completed.
02
Drugs
rosuvastatinfurosemide
03
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2600124934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124934.